PASG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Passage Bio Inc (PASG) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some potential upside based on analyst ratings and technical indicators, the lack of significant positive catalysts, weak financial performance, and absence of trading signals suggest holding off on making an investment at this time.
The MACD is positive at 0.502, indicating bullish momentum, but it is contracting. RSI is at 72.446, which is in the neutral zone, not signaling overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 11.574 and 12.636, while support levels are at 8.136 and 7.074.
The stock has a potential upside in the next week with a 9.79% chance of gain.
No recent news or significant trading trends from hedge funds or insiders. Financial performance remains weak with no revenue and negative EPS. The stock has a 50% chance of declining by -1.31% in the next day.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$12.98M (up 2.03% YoY), and a drop in EPS to -4.08 (-0.73% YoY). Gross margin remains at 0%.
Oppenheimer initiated coverage with an Outperform rating and a $30 price target, citing the pullback as a buying opportunity. Canaccord lowered its price target from $67 to $23 but maintained a Buy rating, reflecting updated expectations for the company's lead programs.
